Targeted Therapy with a Novel Superantigen-based Fusion Protein Against Interleukin-13 Receptor α2-overexpressing...

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Superantigens, like staphylococcal enterotoxin B (SEB), trigger potent immune responses.
• SEB can form complexes with MHC class II (MHCII) and TCR, enabling tumor-targeting strategies.
• Interleukin-13 (IL13) targets IL13 receptor α2 (IL13Rα2), which is overexpressed in glioblastoma multiforme (GBM).

Purpose of the Study:

• To design and evaluate novel fusion proteins combining SEB and IL13 for glioblastoma therapy.
• To assess the stability, binding affinity, and structural characteristics of these engineered proteins.

Main Methods:

• Four fusion proteins (SEB-IL13, SEB-L-IL13, IL13-SEB, IL13-L-SEB) were designed with varying SEB/IL13 arrangements and linkers.
• Bioinformatics tools predicted and refined 3D structures.
• HADDOCK 2.4 server performed docking simulations with IL13Rα2, MHCII, and TCR.
• Molecular dynamics simulations (iMODS) evaluated complex stability.

Main Results:

• The IL13-L-SEB fusion protein exhibited enhanced stability and a longer half-life.
• Docking analysis indicated superior binding affinity of IL13-L-SEB to IL13Rα2, MHCII, and TCR.
• Molecular dynamics simulations confirmed acceptable stability for the IL13-L-SEB docked complexes.

Conclusions:

• The IL13-L-SEB fusion protein is a stable and effective candidate for glioblastoma targeting.
• This engineered protein represents a promising novel therapeutic strategy for cancer treatment.